Shares of Longevity Health Holdings Inc. (NASDAQ:XAGE) soared 155% on Tuesday after the company announced a definitive agreement to merge with True Health Inc., the operator of THPlasma, in an all-stock deal.
The acquisition of THPlasma marks Longevity Health’s latest expansion effort, following its takeovers of Carmell Therapeutics in July 2023 and Elevai Skincare in January 2025. With this move, the company deepens its footprint in the broader health and longevity space. THPlasma focuses on the plasma collection market, which plays a crucial role in addressing the persistent shortage of plasma and plasma-derived therapeutics across the U.S.
Under the terms of the agreement, THPlasma has been assigned a valuation of $59 million, with an additional $20 million earnout tied to future financial performance. This places the total deal value at roughly 2.5 times THPlasma’s projected FY2026 revenue, including the earnout. Longevity stock was priced at $3.00 per share for the purposes of the transaction—representing a 12% premium over its July 11 closing price.
THPlasma, which currently runs two plasma centers in New Jersey, is in the process of scaling up to five locations across New Jersey and Pennsylvania by fiscal year 2025. The company has secured long-term offtake agreements valued at $100 million annually and became cash-flow positive in fiscal year 2024.
Looking ahead, THPlasma expects FY2025 revenue to reach $10 million, with EBITDA of $2 million and net income of $1 million. In FY2026, the firm is projecting explosive growth: $32 million in revenue (a 220% year-over-year increase), $7 million in EBITDA (up 250% YoY), and $4 million in net income (a 325% jump).
Once the transaction closes—anticipated in the fourth quarter of 2025—the combined entity will continue to trade on the Nasdaq under the existing ticker “XAGE.” Leadership will be shared: Longevity CEO and Chairman Rajiv Shukla will become Executive Chairman, while THPlasma founder and CEO George Chi will take the reins as Co-Chairman and CEO.
As part of the announcement, Longevity also confirmed that its planned acquisition of 20/20 BioLabs has been mutually terminated.
Longevity Health Holdings stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.